It's been the same trading pattern the last few we
Post# of 1425
The last few PR's released has shown the company is growing not only with increasing Annihilyzer sales but fluid sales. The ability to shift back and forth is what will fuel increasing rev's.
I also think investors new and old need to realize Annihilyzer system is geared towards healthcare facilities. I say this because it meets all CMS (feds) compliance. PCTL owns the patents and owns the EPA registration. Our sub registrants are geared towards the retail venue's as we've seen PCTL's fluids disinfecting first responder vehicles, restaurants ect. PCTL's distributors can sell Annihilyzer systems and fluids as we've seen with Ace.
All the DD I've seen tells me the company will have increasing rev's and profits in 2020.
The company has a signed agreement with the NHS of the UK. No doubt in my mind once the data is confirmed there will be many Annihilyzer sales into the UK. Not one system has ever been returned. I also think the UK office will turn into the gateway into the EU.
Life will change in many ways after CV-19 runs it's course. As sad as this pandemic has been it's shown the world disinfection is not only needed but mandatory for all industries. Businesses in the disinfection business including PCTL will benefit. Some have said what about competition. Count how many businesses there are in the world plenty to go around. Other companies might fit certain industries better than PCTL and PCTl will fit into industries competitors don't.
One last thing everyone should remember if the fins looked great PCTL would not be on the OTC but the NAS. The company showed 3x revs in the 9 mo's compared to 2018. They also showed over 5x 3mo's revs compared to 2018. They were able to keep expenses down and although there was dilution they didn't even start selling Annihilyzer's until Nov. 2018 less than a year from the the filed Q. tells me the company was growing back then.
For a stock trading just under 4 pennies it's a no brainier IMO given the potential it has.